Core Viewpoint - A class action securities lawsuit has been filed against Applied Therapeutics, Inc. due to alleged securities fraud affecting investors between January 3, 2024, and December 2, 2024 [1][6]. Company Summary - The lawsuit is a response to a Complete Response Letter (CRL) received by Applied Therapeutics from the FDA regarding its New Drug Application (NDA) for govorestat, indicating deficiencies in the clinical application [6]. - Following the announcement of the CRL on November 27, 2024, Applied Therapeutics' stock price dropped significantly from $10.21 per share to $8.57 per share, and further declined to $2.03 on November 29, 2024, and $1.75 on December 2, 2024, marking a total decline of over 80% [6]. - After the disclosure of a "warning letter" from the FDA on December 2, 2024, the stock price continued to fall, reaching $1.69 on December 3, 2024, and further declining to $1.38 on December 4, 2024, and $1.29 on December 5, 2024 [6]. Legal Context - Investors who suffered losses during the specified timeframe have until February 18, 2025, to request to be appointed as lead plaintiff in the lawsuit [4]. - The lawsuit aims to recover losses for investors adversely affected by the alleged fraud [6]. Firm Background - Levi & Korsinsky, LLP has a strong track record in securities litigation, having secured hundreds of millions of dollars for shareholders over the past 20 years [7]. - The firm has been recognized in ISS Securities Class Action Services' Top 50 Report for seven consecutive years as one of the leading securities litigation firms in the United States [7].

Group 1 - A class action has been filed against Applied Therapeutics, Inc. for allegedly misleading investors regarding its lead drug candidate, govorestat, during the period from January 3, 2024, to December 2, 2024 [1][2][7] - The complaint highlights that Applied Therapeutics received a Complete Response Letter (CRL) from the FDA on November 27, 2024, due to deficiencies in the clinical application, leading to a significant decline in stock price from $8.57 to $1.75, representing a total decline of over 80% [2][8] - The company is accused of making misleading statements about the efficacy of govorestat in treating Galactosemia, including positive outcomes from various clinical trials and confidence in its New Drug Application (NDA) [7] Group 2 - Shareholders interested in participating as lead plaintiffs in the class action must submit their applications by February 18, 2025, and can remain absent class members if they choose not to participate [3] - Robbins LLP, the law firm handling the case, has a history of assisting shareholders in recovering losses and improving corporate governance since 2002 [4]

NEW YORK, Dec. 19, 2024 /PRNewswire/ -- The Gross Law Firm issues the following notice to shareholders of Applied Therapeutics, Inc. (NASDAQ: APLT).Shareholders who purchased shares of APLT during the class period listed are encouraged to contact the firm regarding possible lead plaintiff appointment. Appointment as lead plaintiff is not required to partake in any recovery.CONTACT US HERE:https://securitiesclasslaw.com/securities/applied-therapeutics-inc-loss-submission-form/?id=117284&from=4CLASS PERIOD: J ...

NEW YORK, Dec. 18, 2024 /PRNewswire/ -- Rosen Law Firm, a global investor rights law firm, announces the filing of a class action lawsuit on behalf of purchasers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024, both dates inclusive (the "Class Period"). A class action lawsuit has already been filed. If you wish to serve as lead plaintiff, you must move the Court no later than February 18, 2025.So what: If you purchased Applied Therapeutics securities duri ...

SAN DIEGO, Dec. 18, 2024 /PRNewswire/ -- The law firm of Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024, inclusive (the "Class Period"), have until February 18, 2025 to seek appointment as lead plaintiff of the Applied Therapeutics class action lawsuit. Captioned Alexandru v. Applied Therapeutics, Inc., No. 24-cv-09715 (S.D.N.Y.), the Applied Therapeutics class action lawsuit charges ...

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Gainey McKenna & Egleston announces that a securities class action lawsuit has been filed in the United States District Court for the Southern District of New York on behalf of all persons or entities who purchased or otherwise acquired Applied Therapeutics, Inc. (“Applied Therapeutics” or the “Company”) (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024, inclusive (the “Class Period”). The Complaint alleges that on November 27, 2024, Defendant ...

NEW YORK, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Attorney Advertising -- Bronstein, Gewirtz & Grossman, LLC, a nationally recognized law firm, notifies investors that a class action lawsuit has been filed against Applied Therapeutics, Inc. (“Applied Therapeutics” or “the Company”) (NASDAQ: APLT) and certain of its officers. Class Definition This lawsuit seeks to recover damages against Defendants for alleged violations of the federal securities laws on behalf of all persons and entities that purchased or otherwi ...

SAN DIEGO, Dec. 18, 2024 (GLOBE NEWSWIRE) -- Robbins Geller Rudman & Dowd LLP announces that purchasers or acquirers of Applied Therapeutics, Inc. (NASDAQ: APLT) securities between January 3, 2024 and December 2, 2024, inclusive (the “Class Period”), have until February 18, 2025 to seek appointment as lead plaintiff of the Applied Therapeutics class action lawsuit. Captioned Alexandru v. Applied Therapeutics, Inc., No. 24-cv-09715 (S.D.N.Y.), the Applied Therapeutics class action lawsuit charges Applied The ...

ATLANTA, Dec. 18, 2024 (GLOBE NEWSWIRE) -- A shareholder class action lawsuit has been filed against Applied Therapeutics, Inc. (“Applied Therapeutics” or “the Company”) (NASDAQ: APLT). The lawsuit alleges that Defendants made materially false or misleading statements and/or concealed material adverse facts concerning the true state of Applied Therapeutics’ Phase III INSPIRE trial; notably, electronic data capture issues and a dosing error in the dose-escalation phase of the study. If you bought shares of A ...

NEW YORK, Dec. 2, 2024 /PRNewswire/ -- Pomerantz LLP is investigating claims on behalf of investors of Applied Therapeutics, Inc. ("Applied Therapeutics" or the "Company") (NASDAQ: APLT). Such investors are advised to contact Danielle Peyton at [email protected] or 646-581-9980, ext. 7980.The investigation concerns whether Applied Therapeutics and certain of its officers and/or directors have engaged in securities fraud or other unlawful business practices. [Click here for information about joining the clas ...